Calithera Biosciences (NASDAQ:CALA) Now Covered by StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Calithera Biosciences (NASDAQ:CALAGet Free Report) in a research report issued to clients and investors on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Calithera Biosciences Trading Up 150.0 %

CALA stock opened at $0.05 on Friday. The company’s 50 day simple moving average is $0.02 and its 200-day simple moving average is $0.03. Calithera Biosciences has a 12 month low of $0.01 and a 12 month high of $0.50.

Hedge Funds Weigh In On Calithera Biosciences

Several institutional investors and hedge funds have recently modified their holdings of CALA. Affinity Asset Advisors LLC purchased a new position in shares of Calithera Biosciences during the first quarter valued at approximately $404,000. Renaissance Technologies LLC lifted its stake in shares of Calithera Biosciences by 36.5% during the first quarter. Renaissance Technologies LLC now owns 1,853,500 shares of the biotechnology company’s stock valued at $749,000 after buying an additional 496,100 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Calithera Biosciences by 143.2% during the first quarter. Goldman Sachs Group Inc. now owns 123,739 shares of the biotechnology company’s stock valued at $50,000 after buying an additional 72,865 shares during the period. Alyeska Investment Group L.P. purchased a new position in shares of Calithera Biosciences during the first quarter valued at approximately $404,000. Finally, Vanguard Group Inc. lifted its stake in shares of Calithera Biosciences by 23.4% during the third quarter. Vanguard Group Inc. now owns 141,217 shares of the biotechnology company’s stock valued at $415,000 after buying an additional 26,800 shares during the period.

Calithera Biosciences Company Profile

(Get Free Report)

Calithera Biosciences, Inc operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc was incorporated in 2010 and is headquartered in South San Francisco, California.

See Also

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.